Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120

Journal of Molecular Recognition

Volumn 22, Issue 2, 2009, Pages 169-174

  Gopi, Hosahudya ^a   Cocklin, Simon ^a   Pirrone, Vanessa ^a   McFadden, Karyn ^a   Tuzer, Ferit ^a   Zentner, Isaac ^a   Ajith, Sandya ^a   Baxter, Sabine ^a   Jawanda, Navneet ^a   Krebs, Fred C ^a   Chaiken, Irwin M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cell infection; Entry inhibitors; HIV 1 gp120; Peptide triazoles; Surface plasmon resonance

Indexed keywords

CITRUS MAXIMA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; FERROCENE; FERROUS ION; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; METALLOCENE; ORGANOMETALLIC COMPOUND; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SOLUBLE CD4 ANTIGEN; TRIAZOLE DERIVATIVE;

ARTICLE; BINDING SITE; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; PROTEIN BINDING; SYNTHESIS; VIRUS ENTRY;

ANTI-HIV AGENTS; ANTIGENS, CD4; BINDING SITES; CELL PROLIFERATION; CELLS, CULTURED; FERROUS COMPOUNDS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR MIMICRY; ORGANOMETALLIC COMPOUNDS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECOMBINANT PROTEINS; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 63449085889     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.892     Document Type: Article

References (30)

1. Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk Dl, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM. 2004. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 43: 1928-1938.
2. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson 1A. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
3. Chameau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. 1994. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 24: 651-662.
4. Cocklin S, Gopi H,Querido B, Nimmagadda M, Kuriakose S, Cicala C, Ajith S, Baxter S, Arthos J, Martin-Garcia J, Chaiken IM. 2007. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J. Virol. 81: 3645-3648.
5. DeMarco SJ, Henze H, Lederer A, Moehle K, Mukherjee R, Romagnoli B, Robinson JA, Brianza F, Gombert FO, Lociuro S, Ludin C, Vrijbloed JW, Zumbrunn J, Obrecht JP, Obrecht D, Brondani V, Hamy F, Klimkait T. 2008. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem. 14: 8396-8404.
6. Dowd CS, Leavitt S, Babcock G, Godillot AP, Van Ryk D, Canziani GA, Sodroski J, Freire E, Chaiken IM. 2002. Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. Biochemistry 41: 7038-7046. Ferrer M, Harrison SC. 1999. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol.73: 5795-5802.
7. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X, Daly NL, Craik DJ, Jiang S, Lehrer RI, Blumenthal R. 2006. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J. Biol. Chem. 281: 18787-18792.
8. Gopi HN, Tirupula KC, Baxter S, Ajith S, Chaiken IM. 2006. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1. envelope glycoprotein gp120. ChemMedChem. 1: 54-57.
9. Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, Tuzer F, Baxter S, Zentner I, Cockin S, Jawanda N, Miller S, Schon A, Klein J, Freire E, Krebs F, Smith A, Sodroski J, Chaiken I. 2008. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1 envelope gp120. J. Med. Chem. http:dx.doi/org/10.1021/jm070814r
10. Ishino T, Pillalamarri U, Panarello D, Bhattacharya M, Urbina C, Horvat S, Sarkhel S, Jameson B, Chaiken 1.2006. Asymmetric usage of antagonist charged residues drives interIeukin-5 receptor recruitment but is insufficient for receptor activation. Biochemistry 45: 1106-1115.
11. Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJ, Moore JP. 2007. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364: 431
12. Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B. 1999. inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 43: 157-173.
13. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
14. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl, Acad Sci. USA 100: 11013-11018.
15. McFadden K, Cocklin S, Gopi H, Baxter S, Ajith S, Mahmood N, Shattock R, Chaiken I. 2007. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 67: 617-629.
16. Moore JP, Doms RW. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA 100: 10598-10602.
17. Munk C, Wei G, Yang OO, Waring AJ, Wang W, Hong T, Lehrer RI, Landau NR, Cole AM. 2003, The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses 19: 875-881.
18. Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong PD, Roux KH, Sodroski J, Wyatt R. 2005. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 79: 9954-9969.
19. Rostovtsev W, Green LG, Fokin W, Sharpless KB. 2002. A stepwise huisgen cycloaddition process; copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem. Int. Ed. Engl. 41: 2596-2599.
20. Steckbeck JD, Orlov I, Chow A, Grieser H, Miller K, Bruno J, Robinson JE, Montelaro RC, Cole KS. 2005. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J. Virol. 79: 12311-12320.
21. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human mono- clonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
22. Tsibris AM, Kuritzkes DR. 2007. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58: 445-459.
23. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438: 99-102.
24. Vita C, Drakopoulou E, Vizzavona J, Rochette S, Martin L, Menez A, Roumestand C, Yang YS, Ylisastigui L, Benjouad A, Gluckman JC. 1999. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 96: 13091-13096.
25. WHO/UNAIDS (December, 2008). AIDS Epidemic Update, ISBN 9291735426 (http://www.unaids.org/en/KnowledgeCentre/HIVData/ EpiUpdate/EpiUpdArchive/2006/ ).
26. Yuan W, Bazick J, Sodroski J. 2006. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by crosslinker, J. Virol. 80: 6725-6737.
27. Zhang MY, Dimitrov DS. 2007. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr. Pharm. Des. 13: 203-212.
28. Zhang W, Canziani G, Plugariu C, Wyatt R, Sodroski J, Sweet R, Kwong P, Hendrickson W, Chaiken 1.1999. Conformational changes of gp 20 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry 38: 9405-9416.
29. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS. 2003. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol. Meth. 283: 17-25.
30. Zhao 0, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. 2005. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)- oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339, 213-225.